Same Void Count, Different Disease: A Diagnostic-First Look at Nocturia

A field note from Prof. Kari Tikkinen's AUA 2026 talk on nocturia in older adults.

One of the talks that reframed how I think about a common complaint was Prof. Kari Tikkinen's session on nocturia in geriatric patients. As many of you know, I am not a urologist. I am here representing proudP, and I was in the audience taking notes. So this is a high-level account of what I captured, not a clinical interpretation, and I have surely missed nuance. Prof. Tikkinen, of the University of Helsinki, presented an academic synthesis with no industry conflicts, which is part of why it landed so cleanly.

His central argument was simple and a little provocative: in older adults, nocturia is rarely just the prostate, and rarely just a quality-of-life issue. It sits at the intersection of urology and geriatrics, it is independently associated with falls, fractures, and mortality, and it has several distinct mechanisms that produce the same nightly void count but call for completely different treatment. As one of his banner lines put it: same void count, different disease, different treatment.

The case that frames it

He opened with a familiar patient: an 80-year-old man labeled "BPH," whose tamsulosin had failed, waking three to four times a night. He was also tired, had fallen, had ankle swelling, snored, and was on amlodipine and a diuretic. The prompt was deceptively simple: what is the diagnosis?

The point of the case is that a failed alpha-blocker does not confirm obstruction. In this man, the prostate may have very little to do with why he wakes at night.

One symptom, several mechanisms

The reframe at the heart of the talk is that nocturia is not one disease. Tikkinen defined it precisely first: waking from sleep to void, preceded and followed by sleep. That definition forces two questions, not one: why does the patient void, and why did the patient wake?

From there, the same nightly void count can come from very different mechanisms. Large nighttime urine volume (nocturnal polyuria), often driven by leg fluid that redistributes when a patient lies down, by heart or kidney conditions, by evening fluids or diuretics, or by sleep apnea. Reduced bladder capacity, with small frequent voids. A voiding or obstructive picture, where the prostate genuinely is the issue. And sleep-driven nocturia, where the patient wakes first for another reason and voids second. A large 24-hour urine volume is a further pattern to exclude. Each points in a different treatment direction, and they frequently coexist.

Diary before drug

If there was one practical takeaway, it was this: the advance is not a new pill, it is a better diagnosis. And the single most decision-changing step is a frequency-volume diary, sometimes called a bladder diary, before reaching for any drug. A diary is what distinguishes large nighttime volume from a small-capacity bladder from a large 24-hour output. Those look identical as a void count and demand opposite treatments.

He paired the diary with a systematic check for systemic causes across sleep, cardiovascular, renal, endocrine, and neurological domains: check the legs and the blood pressure, ask about snoring and apnea, and review the timing of diuretics and vasodilators like amlodipine. Sometimes, as he put it, nocturia is fluid redistribution, and sometimes a patient voids because they woke, not the reverse.

Operate on obstruction, not on nocturia

For the urologists in the room, the most pointed slide was about surgery. Before offering prostate surgery for nocturia, confirm true obstruction, with selective urodynamics where appropriate to distinguish obstruction from an overactive or underactive bladder, and assess geriatric risk: frailty, cognition, mobility, and polypharmacy. His phrase was memorable: operate on obstruction, not on nocturia. Comorbidity raises the perioperative risk and lowers the chance surgery helps if obstruction was never the driver.

He was equally disciplined about medication. Desmopressin, for example, treats diary-proven nocturnal polyuria and nothing else, and carries real sodium-safety requirements that make it a careful, narrow choice in older adults, not a first move.

Why measurement is the through-line

What stayed with me is that nearly every step in his framework depends on objective data gathered over time rather than a single visit: the diary that defines the phenotype, the voided volumes and flow that separate one mechanism from another, the trend that tells you whether a patient is stable or changing. And the outcomes he cared about were not just void counts, but sleep, falls, function, and safety.

That is the part close to our work. Structured, low-friction home measurement of voided volume and flow is exactly the signal a diary-first, phenotype-based approach needs. proudP and Bladderly are built to capture that kind of data at home over time, which supports the diagnostic step Tikkinen was arguing for rather than replacing the clinical judgment that follows it.

To be clear, Prof. Tikkinen endorsed no product and has no industry ties. I read his synthesis as external validation of a diagnostic-first idea, not as an endorsement of any tool, ours included. The takeaway I left with is the one he ended on: phenotype before you treat, and protect sleep and safety.

See how proudP support objecgtive, diary-based tracking at home.

---

Frequently asked questions

Is nocturia in older men usually caused by the prostate?

Often not. Prof. Tikkinen's AUA 2026 synthesis stressed that nocturia in older adults is frequently non-prostatic, with mechanisms including large nighttime urine volume, reduced bladder capacity, sleep disorders, and systemic conditions. A failed alpha-blocker does not confirm obstruction.

What is the most important first step in working up nocturia?

A frequency-volume (bladder) diary before any drug. It distinguishes nocturnal polyuria from reduced bladder capacity from a large 24-hour urine output, which look identical as a void count but require different treatment.

Should prostate surgery be offered for nocturia?

Only after confirming true obstruction, with selective urodynamics where appropriate, and assessing geriatric risk. As the talk put it, operate on obstruction, not on nocturia.